Wachtell, Latham & Watkins Steer $3.7B Biopharma Deal
Biotechnology company Amgen Inc., led by Wachtell Lipton Rosen & Katz, will purchase Latham & Watkins LLP-steered biopharmaceutical company ChemoCentryx Inc., for an enterprise value of $3.7 billion, the companies announced...To view the full article, register now.
Already a subscriber? Click here to view full article